ArticleMolecular neurobiology2026
Integrative Analysis Reveals Interactions Between Gut Microbiota-Derived Metabolites and the Brain in Parkinson's Disease.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder increasingly associated with gut microbiota alterations, yet the mechanisms by which microbial metabolites influence PD remain unclear. Here, we applied an integrative computational and experimental strategy to identify key gut microbial metabolites and host genes potentially involved in PD. Differentially abundant gut microbes were obtained from the gutMDisorder database and their corresponding metabolites from gutMGene, with predicted protein targets generated using the Similarity Ensemble Approach. Transcriptomic data from PD brain tissues were analyzed to identify differentially expressed genes, which were intersected with metabolite targets, followed by enrichment and protein-protein interaction analyses. Three machine learning algorithms were applied for gene prioritization, while molecular docking evaluated metabolite-gene binding affinities and ProTox3.0 predicted toxicity and blood-brain barrier permeability. In vitro assays further assessed the functional effects of 3-indolepropionic acid in a rotenone-induced SH-SY5Y cell model. Our analyses identified 44 PD-associated microbial taxa linked to 77 metabolites and 905 predicted target genes, with 29 overlapping differentially expressed genes enriched in synaptic signaling and dopaminergic pathways. Dopamine receptor D2 (DRD2) emerged as a central hub gene, with strong docking interactions predicted for two indole metabolites, 3-(1H-indol-3-yl)propanoate and 3-indolepropionic acid. Functional validation showed that 3-indolepropionic acid improved cell viability, reduced apoptosis, and preserved DRD2 expression under neurotoxic stress. Together, these findings suggest that specific gut microbial metabolites may modulate host dopaminergic signaling via DRD2, offering new insights into the microbiota-brain axis and potential targets for further PD research.
Indexed as
Identifiers
42530713What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.